Upgrade to FINVIZ Elite to get real-time quotes, intraday charts, and advanced charting tools. Subscribe to Elite

BOLD

Boundless Bio Inc

Jan 20 • 02:25PM ET

1.25

+0.01 0.49 %

Healthcare • Biotechnology • USA • NASD

Today, 7:06 AMBoundless Bio announces FDA acceptance of its IND for novel Kinesin degrader BBI-940, the planned initiation of first-in-human KOMODO-1 trial in 1H 2026, discontinuation of the POTENTIATE trial, and an extended cash runway into the second half of 2028.

Peers: BLUE NTLA CRSP EDIT SGMO BNGO CERS MESO FATE CLLS

| Held by: VTI VXF IWC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.77	Insider Own	28.92%	Shs Outstand	22.39M	Perf Week	0.49%
Market Cap	27.90M	Forward P/E	-	EPS next Y	-2.10	Insider Trans	0.00%	Shs Float	15.91M	Perf Month	-1.88%
Enterprise Value	-39.91M	PEG	-	EPS next Q	-0.52	Inst Own	39.99%	Short Float	0.41%	Perf Quarter	-9.04%
Income	-61.76M	P/S	-	EPS this Y	35.84%	Inst Trans	1.89%	Short Ratio	0.45	Perf Half Y	8.36%
Sales	0.00M	P/B	0.25	EPS next Y	14.84%	ROA	-35.93%	Short Interest	0.06M	Perf YTD	3.84%
Book/sh	4.92	P/C	0.24	EPS next 5Y	35.63%	ROE	-44.88%	52W High	2.77 -55.01%	Perf Year	-50.94%
Cash/sh	5.25	P/FCF	-	EPS past 3/5Y	-50.29% -	ROIC	-39.37%	52W Low	1.00 24.61%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	5.99% 6.94%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-0.50%	Oper. Margin	-	ATR (14)	0.08	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	10.14	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	53.14	Recom	3.00
Dividend Gr. 3/5Y	- -	Current Ratio	10.14	EPS Q/Q	16.42%	SMA20	1.00%	Beta	-0.12	Target Price	3.00
Payout	-	Debt/Eq	0.45	Sales Q/Q	-	SMA50	4.39%	Rel Volume	5.11	Prev Close	1.24
Employees	64	LT Debt/Eq	0.42	Earnings	Nov 05 BMO	SMA200	0.48%	Avg Volume	143.35K	Price	1.25
IPO	Mar 28, 2024	Option/Short	No / Yes	EPS/Sales Surpr.	-6.44% -	Trades		Volume	569,868	Change	0.49%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-02-25	Initiated	H.C. Wainwright	Buy	$5
May-28-25	Downgrade	Leerink Partners	Outperform → Market Perform	$3
Dec-13-24	Downgrade	Guggenheim	Buy → Neutral
Apr-22-24	Initiated	Piper Sandler	Overweight	$20
Apr-22-24	Initiated	Leerink Partners	Outperform	$25
Apr-22-24	Initiated	Guggenheim	Buy	$24

Today 07:00AM	Boundless Bio Advances Novel Kinesin Degrader Program BBI-940 and Extends Cash Runway (GlobeNewswire)
Nov-24-25 07:00AM	Boundless Bio to Participate in the Piper Sandler 37th Annual Healthcare Conference (GlobeNewswire)
Nov-05-25 07:00AM	Boundless Bio Reports Third Quarter 2025 Financial Results and Business Highlights (GlobeNewswire)
Oct-13-25 04:05PM	Boundless Bio Announces Upcoming Presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
Aug-05-25 07:00AM	Boundless Bio Reports Second Quarter 2025 Financial Results and Business Highlights (GlobeNewswire)
04:58PM	Loading…
Jun-05-25 04:58PM	Boundless Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference (GlobeNewswire)
May-23-25 04:01PM	Boundless Bio Announces Portfolio Prioritization and Runway Extension (GlobeNewswire) -15.58%
May-14-25 12:00PM	Boundless Bio, Inc. (BOLD) Upgraded to Buy: Here's What You Should Know (Zacks)
May-09-25 07:00AM	Boundless Bio Reports First Quarter 2025 Financial Results and Business Highlights (GlobeNewswire)
May-01-25 08:23AM	New Strong Sell Stocks for May 1st (Zacks) -8.52%
Apr-03-25 07:00AM	Boundless Bio to Participate in the Needham Virtual Healthcare Conference (GlobeNewswire) -7.38%
Mar-27-25 07:00AM	Boundless Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights (GlobeNewswire)
Feb-26-25 07:00AM	Boundless Bio to Participate in the Leerink Global Healthcare Conference (GlobeNewswire)
Feb-03-25 10:00AM	Boundless Bio Appoints Robert Doebele, M.D., Ph.D., as Chief Medical Officer (GlobeNewswire)
Dec-12-24 04:01PM	Boundless Bio Announces Pipeline and Leadership Updates (GlobeNewswire) -12.72% -16.61%
07:00AM	Loading…
Nov-25-24 07:00AM	Boundless Bio to Participate in the Piper Sandler Healthcare Conference (GlobeNewswire) +8.94%
Nov-07-24 04:01PM	Boundless Bio Reports Third Quarter 2024 Financial Results and Business Highlights (GlobeNewswire) +5.42%
Nov-05-24 07:00AM	Boundless Bio to Participate in the 2024 Guggenheim Global Healthcare Conference (GlobeNewswire)
Oct-14-24 08:00AM	Boundless Bio Announces Departure of Chief Financial Officer (GlobeNewswire)
Sep-11-24 07:00AM	Boundless Bio to Participate in the 2024 Cantor Global Healthcare Conference (GlobeNewswire)
Aug-13-24 04:28AM	Sluggish enrollment leads Boundless Bio to make 'modest' layoffs 5 months after $100M IPO (FierceBiotech.com)
03:32AM	Boundless Bio, Inc. (BOLD): Why Should You Buy This New Penny Stock Now? (Insider Monkey)
Aug-12-24 10:53PM	BOLD Stock Earnings: Boundless Bio Beats EPS for Q2 2024 (InvestorPlace) -6.19%
04:01PM	Boundless Bio Provides Business Updates Focused on Key Value Drivers and Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Jun-05-24 07:00AM	Boundless Bio to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference (Business Wire)
May-13-24 02:53PM	BOLD Stock Earnings: Boundless Bio Reported Results for Q1 2024 (InvestorPlace) +10.83%
07:00AM	Boundless Bio Reports First Quarter 2024 Financial Results and Corporate Highlights (Business Wire)
May-06-24 08:00AM	Boundless Bio to Present at the Citizens JMP Life Sciences Conference 2024 (Business Wire)
May-01-24 10:05AM	Biotech Innovations Aim to Combat Soaring Cancer Diagnoses by 2050 (PR Newswire)
Apr-14-24 11:37AM	Insiders are Amassing These 10 Stocks in April (Insider Monkey)
08:00AM	Loading…
Apr-11-24 08:00AM	Boundless Bio Announces First Patient Dosed in First-in-Human Phase 1/2 Clinical Trial of BBI-825 in Cancer Patients with Resistance Gene Amplifications (Business Wire)
Apr-08-24 08:00AM	Boundless Bio Presents Preclinical and Clinical Pharmacodynamic Data on its Lead Extrachromosomal DNA (ecDNA)-Directed Therapy, BBI-355, at the American Association for Cancer Research Annual Meeting 2024 (Business Wire) -5.75%
Mar-27-24 06:55PM	Boundless Bio Announces Pricing of Initial Public Offering (Business Wire)

Boundless Bio, Inc. is a clinical-stage oncology company, which is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA. The company was founded by Vineet Bafna, Paul Mischel, Benjamin F. Cravatt, and Jonathan E. Lim on April 10, 2018 and is headquartered in San Diego, CA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BOLD

Boundless Bio Inc

Upgrade your FINVIZ experience